2 December 2025: Reference is made to the stock exchange announcements published
by Oncoinvent ASA (the "Company") on 14 November 2025 and on 17 November 2025,
regarding the commencement of the subscription period in the fully underwritten
rights issue of 260,000,000 new shares in the Company (the "Rights Issue") and
the receipt of subscription rights in the Rights Issue by certain primary
insiders and certain close associates of primary insiders of the Company.
Further reference is made to the stock exchange announcement published by the
Company on 2 December 2025, regarding the final result of the Rights Issue and
the allocation of the new shares.

Certain primary insiders and close associates have been allocated new shares:

  · Charles Gillies O'Bryan-Tear, chairperson of the board of directors of the
Company, has been allocated 2,000,000 shares.
  · Teakay Invest AS, a company closely associated to Ingrid Teigland Akay,
member of the Company's board of directors, has been allocated 664,551 shares.
  · Abakus Invest AS, a company closely associated to Øystein Soug, Chief
Executive Officer of the Company, has been allocated 757,206 shares.
  · Anne Cecilie Alvik, Head of Quality Assurance, has been allocated 40,000
shares.
  · Hadean Capital I AS, a company closely associated to Ingrid Teigland Akay,
member of the Company's board of directors, has been allocated 17,787,881
shares.
  · HVentures Capital I AB, a company closely associated to Ingrid Teigland
Akay, member of the Company's board of directors, has been allocated 8,068,142
shares.
  · Olav Hellebø, member of the Company's board of directors, has been allocated
200,000 shares.
  · Gro E. Hjellum, Chief Operating Officer, has been allocated 100,000 shares.
  · Itza AS, a company closely associated to Tore Kvam, Chief Financial Officer,
has been allocated 454,324 shares.
  · Hadean Growth Fund I AS, a company closely associated to Ingrid Teigland
Akay, member of the Company's board of directors, has been allocated 8,666,991
shares.

Please refer to the attached notifications of trade for further information.

Issuance and delivery of the new shares is subject to the extraordinary general
meeting of the Company to be held on 5 December 2025 approving the required
share capital reduction to reduce the nominal value of the Company's shares (as
further described in section 7.4.3 of the prospectus prepared by the Company),
any other resolutions required to complete the Rights Issue, and the timely
payment for the new shares subscribed for and allocated.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.